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Dreamtime: Version 5.0 of the Australian Guidelines for Preparing Submissions to the 
Pharmaceutical Benefits Advisory Committee (PBAC) 
Paul C Langley, PhD 
Adjunct Professor, College of Pharmacy, University of Minnesota 
  
Abstract 
In September 2016 the Australian Department of Health published Version 5.0 of the Guidelines for Preparing Submissions to the 
Pharmaceutical Benefits Advisory Committee (PBAC). These guidelines, which were first published for comment in 1990, set out how 
to prepare a submission to list a new medicine or medicinal product on the Pharmaceutical Benefits Schedule (PBS). The guidelines give 
instructions on the information required by the PBAC and the Economic Sub-Committee (ESC), the most appropriate form for presenting 
clinical evidence and the standards for an economic evaluation. The purpose of this commentary is to consider whether or not the 
evidence standards proposed and the consequent modeled claims for economic effectiveness meet the standards of normal science: 
are the claims presented to support PBS listing credible, evaluable and replicable. The review concludes that the PBAC guidelines do 
not meet the standards expected in normal science. The absence of empirically evaluable claims means there is no way of judging 
whether they are right or even if they are wrong. If the Guidelines were never intended to support experimentation and systematic 
observation to generate feedback to health system decision makers, then this should be made clear by the PBAC. If not, then 
consideration should be given to redrafting the guidelines to ensure they conform to these standards. Hopefully, future versions of the 
guidelines will address this issue and focus on a rigorous research program of claims assessment and feedback. 
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Introduction 
Australia, in common with countries including the UK, Ireland, 
the Netherlands and New Zealand, has issued guidelines to 
support formulary submissions 1 2 3 4 5. In the US 
recommendations for formulary submission standards have 
been proposed by the Academy of Managed Care Pharmacy 
(AMCP) together with modelling standards proposed by the 
International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) 6 7 8. Guidelines have also been proposed as 
a standard for the European Union under the EUnetHTA 
umbrella 9. A common feature of these guidelines is to 
mandate a reference case where the recommended decision 
framework for chronic disease tracks a hypothetical cohort of 
patients over their lifetime. Comparative product claims are 
expressed as cost utility quality adjusted life years (QALYs). 
 
Previous publications and formulary evaluation commentaries 
in this series have made clear that comparative product claims 
expressed in lifetime cost-per-QALY terms put to one side a 
commitment to the standards  
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of normal science. These standards require modeled claims or 
hypotheses to be credible, evaluable and replicable. 10 11 12 13 
14.  
 
A lifetime cost-per-QALY model is not designed to generate 
evaluable claims 15. It is a construct that is defended by its 
sufficient correspondence to reality. Validation focuses on the 
core model and its assumptions. Whether or not the model can 
support evaluable claims and whether or not these claims 
could ever be evaluated is apparently irrelevant. 
 
In rejecting the standards of normal science, advocates of 
models that are intended to ‘inform’ decision makers in health 
care systems (whatever that means) rather than establish a 
practical research program, put to one side a commitment to 
standards that have been in place since the seventeenth 
century in favor of what may be described as pseudoscience: 
intelligent design rather than natural selection 16. This 
commitment to ‘informing’ decision makers through the 
construction of imaginary worlds in seen in the recently 
released draft of the 4th edition of the Guidelines for the 
Economic Evaluation of Health Technologies: Canada where it 
is made clear that ‘Economic evaluations are designed to 
inform decisions. As such, they are distinct from conventional 
research activities, which are designed to test hypotheses’ 17. 
 
In an effort to meet the standards of normal science, 
guidelines have been proposed by the Program in Social and 
Administrative Pharmacy at the University of Minnesota that 
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reject imaginary constructs in favor of credible, evaluable and 
replicable claims; claims which apply equally well to clinical 
outcomes as well as those for comparative cost-effectiveness 
and budget impact 18. Formulary submissions are to be 
supported by protocols to detail how the claims are to be 
evaluated and reported. This requirement is not new. It was 
put forward as a standard over ten years ago in formulary 
submission guidelines developed for the Wellpoint (now 
Anthem) health system in the US 19 20. 
 
The purpose of this commentary is to consider the economic 
evaluation standards of Version 5.0 of the PBAC guidelines 
from the perspective of normal science: do the guidelines 
support claims for new medicines or medicinal products that 
are credible, evaluable and replicable?  Are the guidelines 
capable of supporting a progressive research program that 
supports experimentation and systematic observation? Are 
the guidelines capable of supporting feedback on product 
performance to physicians, patients and health system 
decision makers?  
 
Guideline Structure 
The purpose of version 5.0 of the PBAC guidelines is to guide 
the preparation of a submission to the PBAC for the public 
funding of a new medicine or medicinal product under the 
Pharmaceutical Benefits Scheme (PBS). The structure of a 
major submission covers: 
 
• Submission Executive Summary 
• Section 1: Context 
• Section 2: Clinical Evaluation 
• Section 3: Economic Evaluation 
o Section 3A: Cost-effectiveness analysis 
o Section 3B: Cost-minimization analysis 
• Section 4: Use of Medication in Practice 
• Section 5: Options to present additional relevant 
information 
The focus of this commentary is on (i) Section 2 - standards for 
clinical evaluation and (ii) Section 3A - standards for economic 
evaluation. 
 
Standards for Clinical Evaluation 
Section 2 of the PBAC guidelines focuses on the collation of the 
best clinical evidence to support the effectiveness and safety 
of the proposed medicine in its approved indication. This 
assessment has eight components: 
 
• a systematic literature search to identify relevant 
clinical trials or studies (sub-sections 2.1-2.2) 
 
• an analysis and interpretation of results of each 
included trial to include comparative treatment effect 
relative to comparators and credibility of findings 
(sub-sections 2.3-2.5) 
• additional analyses of comparative treatment effect 
(in the absence of estimates from the whole trial 
population) (sub-section 2.6) 
• an assessment of the applicability of treatment effect 
evidence for the target Australian population (sub-
section 2.7) 
• therapeutic conclusions for efficacy and safety versus 
comparator (sub-section 2.8) 
This conclusion from sub-section 2.8 forms the basis for the 
economic evaluation in Section 3.  
 
Sub-section 2.1 Literature Search Methods 
This details the search methods to capture all relevant 
randomized trials (or nonrandomized studies) for the clinical 
evaluation. The focus is on randomized trials that compare the 
proposed medicine with the main comparator. If there are no 
direct randomized comparisons the search will identify 
randomized trials for indirect comparison. If there are no 
indirect comparisons, the search will focus on nonrandomized 
studies. 
 
Sub-section 2.2 Identification of Relevant Trials 
This section details the search for and identification of relevant 
trials. Steps required are to: (i) present results using a PRISMA 
flowchart; (ii) list all trials indicating which are 
included/excluded with reason for exclusion; (iii) create a 
master list of included trials; (iv) if applicable, identify trials 
used for indirect comparisons; (iv) describe how the included 
trials are used to support the clinical claim; and (v) attach 
copies of trials. 
 
Sub-section 2.3 Trial design and execution 
The focus of this sub-section is on the risk of bias, internal 
validity, to identify those trials with the greatest scientific 
rigor. Information requested, with results presented in tabular 
form, focuses on the design and conduct of the trial (e.g., 
group allocation, blinding). Risk assessments are also to be 
undertaken for non-randomized studies, together with efforts 
for mitigating risk. The ROBINS-I tool is recommended for 
assessment purposes.  
 
Sub-section 2.4 Trial characteristics 
This sub-section details the individual trial characteristics: (i) 
eligibility criteria and patient/subgroup characteristics; (ii) 
treatments in each arm; (iii) primary and patent relevant 
outcomes; (iv) minimally important difference for outcomes; 
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(v) non-inferiority margins and (vi) cross-reference to source 
documents. 
 
Sub-section 2.5 Trial results for whole trial population 
This sub-section reports the results for the whole trial 
population. Information is required on: (i) effectiveness results 
for each trial for relevant outcomes; (ii) adverse events; and 
(iii) cross reference to source documents. 
 
Sub-section 2.6 Trial results: additional analyses 
Additional analyses include sub-group assessments, meta-
analyses, indirect comparisons and adjustments for treatment 
switching. 
 
Sub-section 2.7 Assessment of differences between the trial 
setting and the Australian setting after listing 
This sub-section explores possible differences between the 
observed comparative benefits and harms in the trial setting, 
and the benefits and harms that are likely to occur in the 
Australian setting after listing on the PBS. 
 
Sub-section 2.8 Interpretation of the clinical evidence 
This sub-section is designed to (i) summarize the overall clinical 
trial evidence and (ii) present the overall therapeutic 
conclusion for comparative effectiveness and safety. The 
summary should address (without repeating earlier 
assessments): 
• the level of evidence 
• the quality of evidence 
• clinical and patient importance of effectiveness and 
safety outcomes 
• statistical precision of the evidence 
• effect size 
• consistency in clinical trial re 
• results 
This sets the stage for the choice of economic evaluation It is 
critical in determining the success of the submission. The 
therapeutic conclusion should be succinct detailing (i) whether 
the product is superior/noninferior/inferior versus the 
comparator and (ii) superior/noninferior/inferior in its safety 
versus the comparator. 
 
Standards for Economic Evaluation 
Section 3 of the PBAC guidelines sets the standards for an 
economic evaluation where the proposed medicine or 
medicinal product is substituted for the main comparator. The 
guidelines note that the information requested is to cover a 
full and transparent description of the evaluation with 
sensitivity analyses to capture uncertainty. The evaluation can 
be either a cost-effectiveness (Section 3A) or a cost 
minimization analysis (Section 3B). The former applies where 
a therapeutically superior product involves higher costs or 
where an inferior product to the main comparator results in 
lower costs. This analysis requires a quantitative assessment of 
incremental costs and outcomes expressed as a cost-
effectiveness ratio. The focus here is on section 3A. 
 
Section 3A: Cost-Effectiveness Analysis 
The preference of the PBAC is for economic evaluations based 
on results from randomized clinical trials with any adjustments 
or additions to account for differences in the population and 
setting, timeframe of analysis or outcomes of interest. 
Evidence standards for the cost-effectiveness analysis and 
submission are detailed in nine sub-sections. These are: 
 
• Overview and rationale of the economic evaluation 
(Section 3A.1) 
• Computational methods and structure of the 
economic evaluation (Section 3A.2) 
• Population and setting (Section 3A.3) 
• Model transition probabilities or variables, 
transformation and extrapolation (Section 3A.4) 
• Health Outcomes (Section 3A.5) 
• Health care resource use and costs (3A.6) 
• Model validation (Section 3A.7) 
• Results of the base case economic evaluation (Section 
3A.8) 
• Uncertainty analysis: model inputs and assumptions 
(Section 3A.9) 
 
Section 3A.1 Overview and rationale of the economic 
evaluation 
The information required to give an overview includes an 
identification of the key components of the economic 
evaluation (in a decision framework), a justification of the type 
of analysis, choice of outcome measures and the primary 
decision that is being addressed. The perspective in the base-
case model should be that of the Australian health system; 
wider societal impacts can be introduced as supplementary 
analyses.  Claims can be made based upon clinical trials. 
Modeled claims would either extrapolate from the trial or be 
developed as a stand-alone model. There needs to be a 
summary of steps translating from trial to model. Discounting 
should be applied for models that extend beyond one-year. 
 
Key components of the economic evaluation include type of 
analysis, outcomes, time horizon, method(s) used to generate 
results, health states, cycle length, transition probabilities and 
software. 
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The preferred modeling framework is cost-utility particularly 
when: (i) there is a claim of incremental life-years gained; (ii) 
there is an improvement in quality, but not quantity, of life; 
and (iii) relevant randomized trials report results using a multi-
attribute utility instrument (MAUI). If a cost-effectiveness 
model is used a case should be made for not translating 
outcomes to utilities. If a cost-consequences or a cost-benefit 
analysis is presented it should be secondary to the base case 
cost-utility or cost-effectiveness model.  
 
Section 3A.2 Computational methods and structure of the 
economic evaluation 
This section details four issues that the submission should 
address: (i) reporting a supplementary literature review for 
additional clinical or epidemiological studies; (ii) reporting and 
justifying the model structure, and the time horizon; (iii) 
describing the modeling technique and (iv) providing an 
electronic copy of the model. 
 
The model structure should capture all relevant health states 
or clinical events along a disease, ensuring it is consistent with 
treatment algorithms. The model structure should be 
informed by the results of the literature review of economic 
evaluations and other clinical and economic literature. The 
time horizon for the model should be defined and justified. It 
should capture all important differences in outcomes between 
the intervention and comparator but not to extend 
unnecessarily beyond this. If there are no mortality 
implications and only temporary quality of life or health effects 
a short term horizon may be appropriate. A lifetime time 
horizon is appropriate if a treatment affects mortality or long 
term/ongoing quality of life. The validity and plausibility of the 
time horizon is determined by the population of the model and 
the realism of the inputs. 
 
Section 3A.3 Population and setting 
The setting of the economic evaluation should be the 
Australian health care system, with the modelled population:  
(i) representing the target Australian population indicated for 
use of the proposed medicine; (ii) with use consistent with the 
treatment guideline; and (iii) any proposed restrictions on 
access to the drug. Relevant patient and clinical characteristics 
may include age, sex, ethnicity, medical condition and severity 
of the medical condition, and comorbidities. The submission 
should detail which patient characteristics are incorporated 
explicitly and which are implicit (associated with use of other 
data) or not included. The submission should detail also how 
heterogeneity in patient characteristics (if relevant) are to be 
captured in the cost-effectiveness analysis.  
 
 
 
Section 3A.4 Model transition probabilities or variables, 
transformation and extrapolation 
In state transition frameworks the transition probabilities 
should be detailed together with other modeled inputs in the 
base-case model. Any translation from surrogate to target 
clinical outcomes should be justified and described, as should 
any extrapolations from trial data. Alternative input data 
should be available to support sensitivity or scenario analyses.  
 
Section 3A.5 Health Outcomes 
The submission should justify the choice of the final health 
outcome for comparative clinical impact, to include quality of 
life or utility scores. The utilities should be presented as point 
estimates (with corresponding standard deviations and 95% 
confidence intervals) for each health state in the model. If a 
MAUI has been used to assign utility weights, the scoring 
algorithm should be reviewed to determine whether the 
preference weights are relevant in an Australian treating 
environment. Any mapping of a patient reported outcome 
measure to preference weights has to be validated. If this is 
not possible, then it should be demonstrated that the outcome 
measures are valid for the target population.  Using different 
published studies to obtain utility weights from the literature 
is discouraged. 
 
Section 3A.6 Health care resource use and costs  
Relevant health care resource items include: 
 
• medicines (direct costs of treatment and medicines 
used to treat adverse reactions) 
• medical services, including procedures 
• hospital services 
• diagnostic and investigational services 
• community-based services 
• any other direct medical costs. 
 
In constructing the model, the submission should define the 
natural units and quantify the number of natural units of the 
resource item provided to patients in each treatment group or 
for each health state patient’s encounter. All unit prices and 
costs should be in Australian dollars with a consistent year of 
analysis. Future costs are valued at current prices consistent 
with using constant prices in the economic evaluation (there 
should be no allowance for inflation or other possible future 
price changes).  
 
Section 3A.7 Model validation 
The model should be validated operationally to support the 
generated results. This may involve tracing patient pathways 
through the model to establish face validity. For external 
validity model traces may be compared with corresponding 
empirical data to check consistency of outcome. Comparing 
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the model outcomes against those for similar models can 
establish cross-validity. Validation should include both data 
sources used in the model (dependent validation) and data 
sources not used in the model (independent validation). 
 
Section 3A.8 Results of the base case economic evaluation 
For the base case model, the submission should provide: 
 
• a calculation of proposed medication cost per 
patient 
• a stepped presentation of the cost-effectiveness 
results and the incremental cost-effectiveness ratio 
(i.e., the key steps involved in transforming the 
comparative clinical data into the modelled base-
case estimate of incremental cost-effectiveness). 
• disaggregated and aggregated costs and outcomes 
• a summary of the base-case estimate of the 
incremental cost-effectiveness ratio 
Section 3A.9 Uncertainty analysis: model inputs and 
assumptions 
The submission should provide: 
 
• a review of the methods to capture uncertainty for 
inputs, translations of inputs and model structure 
• a univariate sensitivity and scenario analysis 
• a review of relevant multivariate analyses and any 
probabilistic sensitivity analyses 
• a summary of the results of the uncertainty analysis 
Discussion 
There is no requirement in the PBAC guidelines for claims for 
competing products to be presented as credible, evaluable and 
replicable. Credible claims, in this context referring to their 
ability to be empirically evaluated not as outcomes that are 
judged credible because the model is considered to be 
sufficiently representative of the ‘real’ world. There is no 
apparent intention in the guidelines that any modeled claim 
should be evaluable. This conclusion applies to models 
irrespective of whether or not they take a short-term or a long-
term or lifetime perspective.  
 
Although the guidelines do not mandate a reference case 
standard, it is clear that in the case of chronic disease that a 
reference standard applies. The approved analytical 
techniques for modeling and the presentation of results are 
consistent with the reference case approach and are no 
different from standards which explicitly take a reference case 
approach in other single payer health systems. This means that 
the PBAC guidelines face the same criticisms that those for the 
UK, Ireland, New Zealand and the Netherlands face: we have 
no idea whether the claims, irrespective of arguments that the 
model has been validated (Section 3A.7), are right or even if 
they are wrong.    
 
Constructed Evidence 
Unfortunately, in the absence of claims that are evaluable and 
replicable, there is no assurance that they are credible. To 
argue that they meet these standards, in the absence of any 
empirical evidence to support the claims, is to adopt a relativist 
position. For a relativist evidence is never discovered, only 
constructed within a particular social community 21.  In a 
community of health economists who accept a reference case 
paradigm to support claims for competing pharmaceutical 
products, relativists would reject any arguments that one body 
of evidence is superior to another. A research program is not 
seen as one that generates new knowledge through claims 
evaluation and replication but one that is judged on its ability 
to persuade and mobilize community support for invented 
facts. Such a research program puts to one side any notion of 
the progress of science, of the process through which new 
evidence overturns consensus views, in favor of rhetoric and 
authority.  
 
Reference case modeling is seen as the ‘gold standard’. The 
acceptance of a gold standard to support the construction of 
imaginary worlds is in direct contrast to the motto of the Royal 
Society (founded 1660; Royal Charter 1662): nullius in verba 
(take no man’s world for it’) 22. As stated on the Royal Society 
website, this motto ‘is an expression of the determination of 
Fellows to withstand the domination of authority and to verify 
all statements by an appeal to facts determined by 
experiment’. This stricture applies equally well to the uncritical 
acceptance of clinical trials where there is little evidence for 
replication of results as well as to the constructed evidence 
and conclusions of long-term and lifetime economic models.  
 
Rejecting constructed evidence to support therapeutic claims 
raises questions as to the relevance of technical standards for 
constructing long-term or lifetime models. The detail in the 
standards required by the PBAC for modeling the base case 
outside of short-term or trial based assessments points to a 
substantial misallocation of time and resources to justify a 
cost-utility model that makes a claim for sufficiency in an 
Australian population. Yet, at the end of the day an effort, with 
the highly prescriptive and probably unnecessarily exhaustive 
requirements of the guidelines which generate, unevaluable 
claims. As an example, the effort put into developing Markov 
models with utility values applied to each health state over a 
lifetime (Section 3A.2), particularly when, as noted below, the 
patient has most likely discontinued that therapy within 2 to 3 
years of the index prescription. 
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Immunity to Failure 
While simulations can fail, lifetime cost-per-QALY modeled 
claims are immune to failure. The only basis on which a non-
evaluable modeled claim can be challenged is on a review of 
the structure of the core model (e.g., state transition models) 
and the assumptions of the model (e.g., state transition 
probabilities). In practical terms, it is possible not only to build 
models that produce competing cost-per-QALY claims as well 
as reverse engineering a model to generate competing results. 
In both the UK and Australia models are subject to 
independent review and appraisal. The assessors may 
recommend structural changes to the core model or challenge 
the basis on which assumptions have been derived (e.g., 
attaching quality of life weights to therapy states). Presumably 
the criterion employed is whether or not the appraisers 
consider the model is a ‘sufficient’ representation of the reality 
captured by the natural course of the disease and the impact 
of competing interventions. As detailed below, neglect of 
anticipated adherence and persistence behavior (which may 
differ between target and comparator arms) may be 
‘sufficient’ to underline the credibility of competing lifetime or 
long-term models. Indeed, any number of competing 
simulations could be constructed around compliance patterns 
yet meet PBAC standards. The same argument would hold, 
again detailed below, for assumption as to long term drug 
pricing and other direct medical cost expenditures. In the 
absence of evaluable claims there is no way competing models 
can be adjudicated and re-assessed. There is no ‘progress’ in 
our understanding of the impact of competing therapies in the 
Australian population. 
 
Validation 
Irrespective of the extent to which model builders claim that 
they are a valid construct and have a pivotal role to play in 
informing decision makers, the validation standards proposed 
in the PBAC guidelines make no claim for validation that 
involves empirical evaluation in target treating populations. 
Section 3A.7 of the guidelines refers only to tracking patients 
through the logic of the model, justifying assumptions 
empirically and comparing the modeled outcomes to those 
from similar models. The question of the feasibility of empirical 
assessment does not arise. 
 
It is worth noting that the PBAC guidelines address the issue of 
plausibility in the timelines for a modeled assessment (Section 
3A 2.2). The validity of the lifetime horizon is not 
independently nominated but is determined by the population 
of the model, and the inputs. If the timeline is implausible, the 
PBAC argues, inputs that are not realistic will result in the 
model predicting a duration of outcomes or survival, estimates 
of QALYs saved and incremental cost-per-QALY savings that 
are themselves implausible. If this argument is applied, as 
noted below, to adherence and persistence with target 
medicines then it leaves little scope for long-term or lifetime 
models. A systematic review of the compliance literature for 
adherence and persistence patterns in the target disease state 
could, presumably, be a key criterion for justifying a model’s 
timelines. This issue is not addressed. 
 
Cost-utility Analysis 
In the absence of a commitment to a protocol to evaluate 
claims expressed in cost-utility terms, the preference for 
utilities as an end-point (Section 3A.1) creates a further barrier 
to evaluation 23 . Utilities are not collected on a regular basis 
by health care systems as part, for example, of searchable 
electronic medical records. There is also the question of choice 
of utility measure or instrument and the possible need to 
crosswalk from one instrument to another. As detailed above, 
claims expressed in lifetime cost-per-QALY terms are 
unevaluable; they are imaginary constructs with no claim to 
credibility. It is worth noting that the PBAC guidelines do not 
mandate a reference cost-per-QALY standard or the 
application of a preferred QALY instrument. It is not clear from 
the PBAC guidelines how competing submissions within a 
disease area utilizing competing quality of life instruments are 
to be evaluated. 
 
The issue of following the NICE model and applying cost-per-
QALY willingness-to-pay thresholds as a resource allocation 
and pricing tool has, apparently, not arisen. If cost-per-QALY 
thresholds (e.g., AUS$50,000 per quality life year saved) are 
not decision criteria then the application of lifetime cost-utility 
modeling standards, particularly where there is no standard 
instrument, seems redundant.  
 
Clinical Standards 
Although the clinical standards for evidence to support overall 
therapeutic claims for the product detailed in Section 2 of the 
guidelines are appropriate (if not overly prescriptive), there 
are two issues that are not addressed. These are: (i) evidence 
for the replication of clinical efficacy and safety claims for the 
pivotal phase 2 and phase 3 trials’; and (ii) evidence of 
adherence to and persistence with therapy for the new 
product and the comparator. Clearly, attention needs to be 
given to how claims for efficacy and safety as well as 
comparative adherence and persistence translate to an 
Australian treating environment, but these are best seen as 
secondary considerations to the reproducibility of claims (see 
below) and compliance. As will be discussed below, these 
issues provide, along with claims for treatment effect in an 
Australian setting, key elements in the case for protocol driven 
claims assessment and reporting. 
 
Long-term Uncertainty 
One possible defense of non-evaluable simulations is that 
concerns with a model or simulation as a ‘sufficient’ 
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representation of the real world is taken account of by 
capturing structural and parameter uncertainty. This is not a 
tenable argument as it sidesteps the issue of credible claims 
and their evaluation. Any number of competing lifetime or 
long-term simulation could be constructed with account taken 
of structural and parameter uncertainty, accompanied by 
tornado diagrams, cost-effectiveness acceptability curves and 
even value of information exercises to fill the gaps in the 
modeled claims. However much we try to embellish the 
modeled imaginary world the fact remains that we don’t know, 
and we will never know, whether the announced claims for 
long-term or lifetime comparative therapeutic benefit are right 
or even if they are wrong. 
 
Replication of Clinical Claims 
The guidelines do not, as far as can be ascertained, address the 
issue of the replication of clinical claims. It is all well and good 
to ask for spreadsheet summaries of the relevant RCT data, 
supported in the absence of head-to-head trials with network 
meta-analysis and other assessments of comparative efficacy 
(but not effectiveness), but that makes a number of implicit 
assumptions regarding acceptance of the quality and 
replicability of the RCTs themselves. There is now an abundant 
literature on irreproducibility in scientific research, including 
Amgen’s attempts to reproduce benchmark studies, Bayer’s 
validation of new drug target claims and an increasing failure 
rate where Phase 3 trials attempt to reproduce Phase 2 results 
24 25 . At the same time, pre-registration of National Heart, 
Lung and Blood Institute trials since 2000 has been associated 
with a decline in the reporting of positive results 26. In a survey 
undertaken by the journal Nature over 70% of researchers 
have tried and failed to reproduce another scientist’s 
experiments and over 50% have failed to reproduce their own 
experiments 27. Given these concerns, it could be argued that 
they place a premium on the need to reproduce clinical claims 
in target Australian patient populations.  
 
Adherence and Persistence 
A puzzling feature of lifetime reference model claims is the 
neglect of adherence and persistence behavior. As noted, the 
PBAC guideline is no exception. Nowhere in the instructions for 
constructing the imaginary reference case is there any 
guidance on including (possibly imaginary) adherence and 
persistence behavior. This appears an odd oversight as the 
guideline is explicit in the requirement for a default lifetime 
model. If this implies that the hypothetical patient cohort are 
persistent with therapy over their lifetime, this flies in the face 
of decades of accumulated evidence which shows that by the 
end of two years from an index prescriptions, probably less 
than one third of patients are persistent with therapy with an 
even smaller proportion maintaining a adherence at a clinically 
meaningful level 28. If this is the case, then to model competing 
therapies assuming full compliance over the lifetime of the 
patient cohort would seem pointless.  
 
In the case of non-valvular atrial fibrillation, to give an 
example, a recent study by Yao et al compares adherence 
patterns for warfarin with those for rivaroxaban, dabigatran 
and apixaban and their impact on risk of stroke and major 
bleeding 29. During a median follow up of 1.1 years, only 47.5% 
of NOAC patients were adherent, defined as a medication 
possession ratio (MPR) of ≥ 80%. Adherence to warfarin was 
40.2%.  Apixaban had the highest unadjusted adherence 
(61.9%) and dabigatran the lowest (38.5%). The rivaroxaban 
rate was 58.4%. Applying a multivariate logistic regression, 
adjusted adherence rates were 38.7% for warfarin and 47.5% 
for all NOACs. Higher rates of adherence were found across all 
treatments for those at higher risk. For those with a CHAa2DS2-
VASc ≥ 4 the warfarin adherence was 53.4% and the average 
for the NOACs 59.8%.  
 
Persistence with NOACs has been reported in three recent 
observational studies. Forslund et al utilizing data from the 
administrative health register of the Stockholm region 
evaluated crude and adjusted persistence from the index OAC 
prescription. In the period April 2011 to December 2014 30. At 
the end of the first year crude overall persistence was 88.2% 
and 82.9% at the end of the second year. Persistence with 
warfarin at the end of the first year was 85.0%, apixaban 
85.9%, dabigatran 74.4% and rivaroxaban 77.4%. In the UK, 
Martinez et al reported on persistence with longitudinal data 
from the Primary Care Clinical Practice Research Datalink 
between January 2011 and May 2014 31. Persistence with 
warfarin at the end of the first year was 63.6$ and 79.2% for 
all NOACs. In Germany, Beyer-Westendorf et al reported 
persistence from primary care patients at 180 days of 66.0% 
for rivaroxaban, 60.3% for dabigatran and 58.1% for VKA. At 1-
year corresponding persistence estimates were 53.1%, 47.3% 
and 25.45% respectively. An MPR ≥ 0.8 was found for 61.4% of 
rivaroxaban and 49.5% of dabigatran patients 32. 
 
Longer term studies suggest that by 3 years from index 
prescriptions no more than 30% of patients met the standard 
of ≥ 80% days covered. There are limited data for longer 
periods. Experience in Australia, for example, in the period 
November-December 2013 to March 2015 with records from 
the Pharmaceutical Benefits Scheme reported by Simons et al 
found that for index prescriptions in a sample of 1,471 atrial 
fibrillation patients  with a mean age of 76 years on NOACs and 
74 years on warfarin found that 62% discontinued within 12 
months 33. The corresponding figure for NOACs was 30%. 
Overall, 9% of those on NOACs failed to pick up the first repeat 
prescription compared to 14% of those on warfarin. 
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These estimates suggest that by the end of one year after the 
index prescription persistence with warfarin is in the range 60 
to 70% with a corresponding NOAC rate of 70 to 80%. By the 
end of year 2, persistence is likely to be 15 to 20% lower. 
Beyond two years is sheer speculation, although it would not 
be unreasonable, given evidence for persistence in other 
chronic disease states that the overwhelming majority of 
patients have discontinued within 3 to 4 years. Given the age 
at which treatment is usually initiated for atrial fibrillation, 
deaths to patients need to be factored in to persistence 
estimates. In the edoxaban pivotal trial, for example, 10-8% of 
patients died before the end of the trial. Under reasons for 
discontinuation death was given in 3.1% of warfarin patients 
and 2.8% of edoxaban patients. 
 
It is unlikely that patterns of adherence and persistence in 
Australian target populations will be different from those 
reported in the US and Europe. Even so, estimates of 
adherence and persistence vary and it would be appropriate 
not only to include estimates in modeled claims but to 
evaluate assumptions in treatment settings. 
 
Lifetime Costs 
A further puzzling feature is the assumption that current prices 
and costs of resource inputs (corrected for discounting) remain 
unchanged over the lifetime of the hypothetical patient cohort 
(Section 3A.6) . The PBAC guidelines ask that no account be 
taken of possible inflation and, by implication, any allowance 
for the future prices of any resource item. Again, this seems an 
odd requirement if the object is to present a model of long 
term or lifetime costs and benefits. In the US, for example, 
there is again ample evidence for pricing strategies (price 
gouging?) by manufacturers for ongoing semi-annual and 
annual price increases both over the patent life of a drug and 
beyond. The price increases being typically accompanied by 
co-payment waivers, coupons and other discounts to maintain 
market share. In the case of disease modifying treatments 
(DMTs) in multiple sclerosis a recent study of the trend in 
annualized drug costs for nine DMTs from 1993 to 2014 found 
increases ranging from 7.9%. to 35.7% 34.  Four of the DMTs 
had annualized cost increases greater than 20% and four in the 
range 13% to 16.8%. While these annualized changes were two 
to three time bigger than in other countries, the potential for 
annualized price increases together with possible price 
increases in direct medical costs should, presumably, be 
factored into reference case models. Lifetime cost increase 
assumptions may, of course be irrelevant if the majority of 
patients have discontinued therapy or report low rates of 
medication possession within 2 to 3 years from product listing 
on the PBS. 
 
Changing government policies towards drug pricing under the 
PBS in Australia are difficult to predict. It should not be 
assumed that PBS ‘protection’ would reduce price increases 
overall and over the lifetime of the treating cohort. The cost of 
a drug would include both co-payments over and above PBS 
coverage as well as off-label use (e.g., in cancer protocols) 
where funding is absent 35.  
 
Pipeline Competitors  
It is unlikely, over the lifetime of a patient cohort, that there 
will be no therapies entering the market place to compete with 
and replace existing medications. In the reference case model 
this is not the case. Patients are assumed to remain with the 
indicated drug over their lifetime. Again, this flies in the face 
of evidence for drug turnover in target populations where 
patients are switched to new therapies. This switching may 
reflect a lack of response to the index drug in the treatment 
arm or may involve moving to a combination therapy. Again, 
this appears an odd assumption but one that is, unfortunately, 
driven by the focus on constructing evidence to establish 
credibility rather than on a more practical perspective of 
evaluating claims for feedback to physicians and formulary 
committees.  
 
Next Generation Sequencing 
The likelihood of competitor therapies and therapy 
combinations is also made more likely by the introduction of 
next generation sequencing (NGS) where assay platforms will 
recommend linking sub-groups of patients defined by 
mutation clusters to monotherapy or combination therapies  
36. An obvious application is in late stage cancer but there will 
be applications earlier in the treatment pathway. In these 
scenarios there will be a premium placed on tracking evaluable 
claims and reporting in real time to clinicians and health 
system decision makers on clinical outcomes and resource 
utilization. If a disease area or target tumor group is 
characterized by a distribution of patients by mutation cluster, 
then a simplistic reference case model is hardly a viable basis 
for therapy choices when multiple pathways are involved and 
patients are individually selected for an assay driven 
intervention. 
 
Redrafting the Australian Guidelines 
A possibly surprising conclusion, given the concerns expressed 
above as to the shortcomings of the latest PBAC guidelines, is 
that the present format can be relatively easily refocused to 
support claims that are credible, evaluable and replicable. The 
critical step is to revisit modeled study timelines. Putting in 
place two requirements that: (i) claims must be evaluated 
within a two-year timeframe from PBS listing; and (ii) that the 
PBAC submission should be accompanied by a protocol 
detailing how the claims are to be assessed would effectively 
overcome claims that the guidelines lack scientific rigor. 
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The timeline flexibility is recognized in the guidelines. Those 
making a submission are asked to justify the modeled timeline 
assumptions whether these are extrapolated from an RCT or 
are part of a de novo model framework. Redrafting would 
require a statement that the preferred timeline should be no 
more than 2-years. If a manufacturer wishes to argue that the 
anticipated benefits from their product against the existing 
standard of care will only be realized in a longer timeframe, 
then they should be asked to submit a protocol detailing short-
term surrogate markers. This is unlikely to occur if, as the 
evidence would suggest across the majority of disease states, 
that within two years the majority (if not the overwhelming 
majority) of patients will have discontinued therapy. A lifetime 
perspective is, quite clearly, redundant if any benefits from a 
new product over a comparator are to occur while patients are 
clinically adherent to therapy. 
 
To reinforce the preferred 2-year timeframe requirement, 
extrapolated or modeled claims should be required to include 
anticipated adherence and persistence behavior. This behavior 
should be required to be reported as part of the study protocol 
with summary measures, for example, to include median time 
to discontinuation of therapy and proportion of patients 
maintaining a medication possession ratio (MPR) or days 
covered by therapy (DCT) > 0.8. Clearly, factoring in adherence 
and persistence will qualify long-term claims for comparative 
product performance expressed in terms of discounted QALYS 
and costs per QALY adjusted life years. This is unavoidable yet 
desirable. It does not mean that QALYs and the application of 
cost-utility models are necessarily abandoned but that 
submissions to the PBAC should make the case for their 
relevance within a 2-year timeframe. 
 
An interesting corollary here is that if the benefits of a 
potential new therapy are qualified significantly by anticipated 
adherence and persistence behavior, then the manufacturer 
may propose an intervention strategy (funded by the 
manufacturer) to improve such behavior. This could be 
justified in cost-effectiveness terms where the benefits from 
improved adherence and compliance are set against the costs 
of implementing and monitoring the intervention. This may be 
as simple as linking patients to an app that reminds them to 
continue their medications. Indeed, the PBAC may even reject 
a submission in the absence of an adherence and persistence 
strategy.    
 
Focusing on a 2-year timeframe will reinforce claims for clinical 
impact. As the majority of RCTs and attempts to make indirect 
comparisons are typically short term, (with the typical RCT not 
extending beyond 6 months) extrapolating clinical benefits 
from a short timeframe will avoid trying to justify longer term 
and more uncertain benefits.   
 
The PBAC, in redrafting the guidelines to accommodate a 2-
year timeframe will have to judge the extent to which it makes 
sense to require submissions to incorporate the technical 
modeling standards that characterize the construction and 
reporting of claims from lifetime imaginary worlds. Rejecting 
attempts to model the long-term course of a disease does not 
mean throwing the bathwater out with the baby, but it may 
mean reconsidering the relevance not of simple decision 
frameworks but those frameworks such as Markov processes 
that are designed to support the construction of lifetime 
imaginary worlds. Many of the standards and processes 
detailed in the PBAC guidelines will be relevant to the 
construction of short-term claims models. Just as the 
reference case modeled outcomes can be expressed as total 
costs and outcomes, incremental costs and outcomes and 
incremental cost-effectiveness ratios, so short-term claims can 
be expressed in these terms. Again, the present guidelines give 
considerable scope over the choice of decision model 
framework as long as long-term or lifetime timelines are put to 
one side. 
 
Adopting a short term time horizon will mean that the PBAC 
will have to drop quality of life as the preferred outcome. In a 
timeframe as short as two years claims expressed in quality life 
years saved may make little sense. The exception here may be 
claims in end-stage cancer interventions or other disease 
states where the focus is on months rather than years in 
patient survival. Otherwise, focusing on clinical and cost-
effectiveness claims where endpoints are defined as clinical 
markers will not only support claims replication from phase 3 
trials but may be more relevant to patients and physicians.  
 
In redrafting the guidelines, the question of evaluating claims 
is not a ‘one-off’. Agreeing a claims assessment protocol sets 
the stage for claims replication. With claims assessment within 
a 2-year timeframe, there is ample scope for evaluating 
feedback from a claims protocol. The protocol could be 
administered in a number of treatment settings to capture 
both heterogeneity in response and its determinants as well as 
more specific claims targeted at sub-populations. Evaluations 
which may be better focused on modeled cost-effectiveness 
rather than cost-utility claims. A reassessment of secondary 
outcome claims (e.g., patient satisfaction, comorbidity 
outcomes) and more detailed assessments of the 
determinants of compliance behavior could be a requirement. 
The PBAC could also consider sponsoring training programs for 
protocol development as rigorous and well managed protocols 
for either experimental or observational are the key to 
effective assessments. 
 
Life is, of course, more interesting if clinical and cost-outcomes 
claims fail. Protocols should be judged on their rigor: how high 
is the bar for claims to be accepted?  Is the protocol designed 
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to minimize false positives? As noted above, there are ongoing 
concerns over the ability to replicate RCT claims, even when 
the claims are based on two well conducted clinical trials have 
been accepted by regulators. The concern of the PBAC should 
be for the implications of including unreproducible or at least 
potentially dodgy clinical data as input to a speculative long-
term cost-per-QALY model to support lifetime cost-per-QALY 
claims. A 2-year assessment timeframe would avoid promoting 
clinical and cost-effectiveness claims that are immune to 
failure. At the same time a protocol would allow a review of 
claims for clinical effectiveness in target Australian 
populations. 
 
Conclusion 
From the perspective of normal science, constructed evidence 
for product impact claims is not acceptable. Regardless of how 
decision modeling is defended by the application of validation 
standards, the treatment of uncertainty and the application of 
value of information techniques, in the last resort the model 
stands or falls on its ability to generate credible, evaluable and 
replicable predictions. To argue that constructed imaginary 
worlds can inform decision makers is to put aside the 
standards of normal science in favor of claims which can never 
be evaluated. The latest version of the PBAC guidelines fail to 
meet this standard. If these guidelines are to be seen as 
credible then they must abandon constructing imaginary 
worlds in favor of evaluable and replicable claims for 
comparative product performance.  
 
Unfortunately, the imaginary constructs of the status quo in 
Australia may be seen as the preferred option. Redrafting the 
guidelines will be seen as unrealistic; imposing an unnecessary 
burden on both manufacturers and the PBAC. Irrespective of 
the potential benefits to patients and physicians Formulary 
and pricing decisions driven by the construction of imaginary 
worlds may be agreed by the parties, after 25 years of PBAC 
submissions, to be mutually advantageous and the least 
troublesome option. 
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